Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_assertion type Assertion NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_head.
- NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_assertion description "[To address these issues, we have investigated the MGMT methylation status, clinical and magnetic resonance imaging characteristics, and relevant genetic features (loss of heterozygosity on 17p and 19q, EGFR amplification, and p53 mutations) in a retrospective study on 86 patients affected by glioblastoma multiforme: 72 patients had a clinical history indicating de novo insurgence of the tumor and the remaining 14 were secondary glioblastoma multiforme.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_provenance.
- NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_assertion evidence source_evidence_literature NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_provenance.
- NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_assertion SIO_000772 17473190 NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_provenance.
- NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_assertion wasDerivedFrom befree-20140225 NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_provenance.
- NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_assertion wasGeneratedBy ECO_0000203 NP773005.RAdqG7e_TeB_VJlrRxNR8njlk3FZqu7Xys5fQtU2dC2Cw130_provenance.